Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BVS vs COCH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BVS Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

BVS Overall Winner 6-Pillar Tally: BVS 5 – 1 COCH Matrix Metrics: BVS 8 – 2 COCH

As of Nov 20, 2026, Bioventus Inc. (BVS) is the stronger overall head-to-head candidate over Envoy Medical, Inc. (COCH) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BVS carries a Unified Composite Score of 46.2/100 (HOLD) at $9.88 (11.1x Forward P/E, 10.1% operating margin), whereas COCH carries 35.1/100 (SELL) at $6.70 (N/M Forward P/E, -10261.0% operating margin).

  • Growth vs. Quality Trade-Off: BVS earns the overall head-to-head edge with a stronger Unified Composite Score (46.2/100 HOLD vs. COCH 35.1/100 SELL) and 0.85β · 74% Vol risk profile, whereas COCH leads top-line expansion (+57.1% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: BVS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.8); meanwhile COCH trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 77.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BVS vs COCH
BVS NASDAQ Head-to-Head Winner
Bioventus Inc. Class A Common Stock
Surgical & Medical Instruments & Apparatus
$9.88
-0.7% 1D
Market Cap $681.3M
TTM Revenue $586M
Forward P/E 11.1x
Beta / 30D Vol 0.85β · 74% Vol
Unified Composite Score
46.2 / 100 HOLD
Tech 35.0 Fund 49.0 Flow 64.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.4%), weak momentum, RSI 29
RSI-14: 28.8 · SMA20: $11.75 · SMA50: $12.81
COCH NASDAQ
Envoy Medical, Inc. Class A Common Stock
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$6.70
+0.0% 1D
Market Cap $51.9M
TTM Revenue $231,000
Forward P/E N/M
Beta / 30D Vol 4.94β · 3352% Vol
Unified Composite Score
35.1 / 100 SELL
Tech 50.0 Fund 27.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (348.7% over 20 days), RSI 78
RSI-14: 77.7 · SMA20: $6.79 · SMA50: $3.12

6-Pillar Scorecard Institutional Category Breakdown (BVS 5 – 1 COCH)

Columns: Metric · BVS · COCH
1. Valuation Multiples BVS
Forward P/E 11.1x N/M
Trailing P/E 12.3x N/M
PEG Ratio 1.20x N/M
EV / Revenue 1.5x 119.2x
2. Growth & Scale BVS
Revenue Growth (YoY) +2.7% +57.1%
Earnings Growth (YoY) +69.7% +0.0%
TTM Revenue (USD) $586M $231,000
Market Cap $681.3M $51.9M
3. Profitability & Quality BVS
Gross Margin 68.7% N/A
Operating Margin 10.1% -10261.0%
Net Profit Margin 9.8% 0.0%
Return on Equity (ROE) 25.8% 0.0%
4. Balance Sheet & Cash Flow BVS
Cash Generation (TTM) $85M -$21M
Cash Flow Margin 14.5% N/A
Net Cash / Leverage $199M Net Debt (0.96x D/E) $24M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning COCH
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 448.1% (100th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat BVS
OpEx & R&D Intensity 58.6% of Rev ($343M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BVS (8) vs COCH (2)
Institutional Metric BVS COCH Criterion Row Edge
Market Capitalization
Scale
$681.3M $51.9M Larger Scale BVS
Trailing P/E Ratio
Valuation
12.3x N/M Lower Multiple BVS
Forward P/E Ratio
Valuation
11.1x N/M Lower Multiple BVS
Revenue Growth (YoY)
Growth
+2.7% +57.1% Higher Growth COCH
Operating Margin (TTM)
Profitability
10.1% -10261.0% Higher Margin BVS
Net Profit Margin
Profitability
9.8% 0.0% Higher Margin BVS
Return on Equity (ROE)
Capital Efficiency
25.8% 0.0% Higher ROE BVS
52-Week Range Position
Momentum
36% ($6–$16) 89% ($0–$7) Stronger Trend COCH
Beta / 30D Volatility
Risk Regime
0.85β · 74% Vol 4.94β · 3352% Vol Lower Realized Risk BVS
Unified Institutional Score
Composite Signal
46.2 / 100 (HOLD) 35.1 / 100 (SELL) Higher Composite BVS
Trailing 12M Revenue (USD)
Operating Scale
$586M $231,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
68.7% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.20x PEG · 1.5x EV/Rev N/M PEG · 119.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$85M ($199M Net Debt (0.96x D/E)) -$21M ($24M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon COCH +1058.66 pp
BVS: -34.31% · COCH: +1024.35%
3M Horizon COCH +827.41 pp
BVS: -29.53% · COCH: +797.88%
6M Horizon COCH +838.52 pp
BVS: +6.47% · COCH: +844.99%
1Y Horizon COCH +796.38 pp
BVS: +47.02% · COCH: +843.4%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BVS Revenue COCH Revenue BVS Op. Margin COCH Op. Margin Margin Leader
FY2019 $340M N/A 9.2% N/A BVS
FY2020 $320M N/A 6.6% N/A BVS
FY2021 $430M N/A 2.8% N/A BVS
FY2022 $510M $0M -32.7% -3673.4% BVS
FY2023 $510M $0M -16.0% -5809.8% BVS
FY2024 $570M $0M -2.7% -8558.2% BVS
FY2025 $570M $0M 9.5% -9240.7% BVS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BVS BREAKDOWN
76d in phase · OBV DISTRIBUTION
Current IV 448.1%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact BVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
COCH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact COCH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BVS Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $681.3M market capitalization and 10.1% operating margin.
OpEx & R&D Reinvestment 58.6% of Rev ($343M)
90D Engineering Disclosures 0 Published
COCH Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $51.9M market capitalization and -10261.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BVS vs COCH Key Questions & Quantitative Answers

As of Nov 20, 2026, Bioventus Inc. (BVS) is the stronger overall head-to-head candidate over Envoy Medical, Inc. (COCH) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BVS carries a Unified Composite Score of 46.2/100 (HOLD) at $9.88 (11.1x Forward P/E, 10.1% operating margin), whereas COCH carries 35.1/100 (SELL) at $6.70 (N/M Forward P/E, -10261.0% operating margin). Growth vs. Quality Trade-Off: BVS earns the overall head-to-head edge with a stronger Unified Composite Score (46.2/100 HOLD vs. COCH 35.1/100 SELL) and 0.85β · 74% Vol risk profile, whereas COCH leads top-line expansion (+57.1% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: BVS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.8); meanwhile COCH trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 77.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BVS leads the Growth & Scale pillar: BVS posts +2.7% YoY revenue growth and +69.7% YoY earnings growth on $586M TTM revenue (68.7% gross margin, 10.1% operating margin), compared with COCH at +57.1% YoY revenue growth and +0.0% YoY earnings growth on $231,000 TTM revenue (N/A gross margin, -10261.0% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), BVS cumulative revenue shifted +67.6% while COCH shifted N/A. In operating R&D and SG&A reinvestment, BVS deploys 58.6% of Rev ($343M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for COCH.

BVS screens cheaper on headline valuation multiples. BVS trades at 11.1x Forward P/E, 12.3x Trailing P/E, 1.20x PEG, and 1.5x EV/Revenue (14.5% FCF margin), whereas COCH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 119.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BVS (25.8% ROE) versus COCH (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, BVS carries 448.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.85β · 74% Vol realized risk). By comparison, COCH carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.94β · 3352% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.